Search

Introduction: Antireflux surgery is commonly associated with significant recurrence and complication rates, and several surgical techniques have been proposed to minimize them. The aim of this study is to evaluate the results of a fundoplication with extensive dissection of the esophagogastric junction 1 and 3 years after the procedure., Methods: Retrospective observational study including 178 patients with gastroesophageal reflux disease or hiatal hernia who underwent fundoplication with extensive dissection of the esophagogastric junction between 2015 and 2020. Hernia recurrence, symptoms and quality of life at 1 and 3 years after surgery were assessed by barium transit, endoscopy and questionnaires for symptoms and quality of life (GERD-HRQL)., Results: Heartburn rate was 7.5% and 10.7% at 1 and 3 years respectively, regurgitation 3.8% and 6.9% and dysphagia was 3.7% and 7.6%. The presence of hiatal hernia was evident preoperatively in 55.1% and in 7.8% and 9.6% at follow-up and the median GERD-HRQL scale was 27, 2 and 0 respectively. There were no cases of slippage of the fundoplication or symptoms suggestive of vagal injury. No differences were found when comparing the different types of fundoplication in terms of reflux and recurrence or complications., Conclusions: Fundoplication with extensive dissection of the esophagogastric junction contributes to correct positioning and better anchorage of the fundoplication, which is associated with low rates of hiatal hernia and reflux recurrence, as well as absence of slippage and lower possibility of vagal injury., (Copyright © 2023 AEC. Published by Elsevier España, S.L.U. All rights reserved.)

Objective: To determine the incidence of paclitaxel and docetaxel infusion-associated reactions, and the likely causes that may trigger them., Method: Cohort study of the paclitaxel and docetaxel infusions carried out at a tertiary hospital from July of 2010 to December of 2011 (18 months). For each infusion, the clinical data and the drug-related data were recorded. When a reaction occurred during the infusion the following data were specified: type, severity, if treatment withdrawal was needed. The clinical charts and treatment orders were reviewed. The follow-up of the infusions were done by contacting the day-care hospital nurses. A descriptive study was done for the most relevant variables included in the follow-up and we analyzed if any of them could have had an influence on the occurrence of the reactions., Results: During the study period, 357 paclitaxel and docetaxel infusions were administered to 92 patients: mean age 61.4 years (SD 11.1), 50.0% were female. 9 infusion reactions affecting 8 patients occurred, all of them caused by docetaxel (c2 = 8.3, p = 0.004); 14.5% of the patients receiving it, and always during the first or second treatment cycle. The variables significantly associated to the occurrence of the reaction were: lung cancer (p< 0.005), docetaxel-cisplatin regime (p< 0.005), receiving the drug as first line (p=0.021), and non-advanced disease (p = 0.014)., Conclusions: At our hospital, docetaxel is the taxane that has provoked the most frequent safety problems during the infusion., (Copyright © 2013 SEFH. Published by AULA MEDICA. All rights reserved.)